Mallinckrodt (NYSE:MNK) and Novoteris, LLC announce that
Health Canada has signed off on a pilot study evaluating inhaled nitric
oxide therapy Thiolanox in COVID-19 patients at Vancouver Coastal
Health Authority facilities. Recruitment should start in the next few
days. Shares up 28% premarket.
CytoDyn (OTCQB:CYDY) has filed a second clinical trial protocol
with the FDA to treat critically ill COVID-19 patients with leronlimab
under the same IND as its recently launched Phase 2 study in patients
with mild-to-moderate symptoms. Target enrollment is 342 subjects.
Centene (NYSE:CNC) will cover the costs
of COVID-19-related treatments for Medicare, Medicaid and Marketplace
members. It has also eliminated the need for providers to collect
co-pays and authorization requirements for said treatment.
Henry Schein (NASDAQ:HSIC) will be the exclusive distributor
of a second rapid point-of-care blood test for COVID-19 developed by
privately held BioMedomics and available through Becton, Dickinson and
Company (NYSE:BDX). HSIC up 2% premarket.
Flexion Therapeutics (NASDAQ:FLXN) has withdrawn its 2020 guidance and suspended its active clinical trials.
Aytu BioScience (NASDAQ:AYTU) has received a shipment of 100K rapid blood tests from the manufacturer. Relabeling is in process. Orders will be filled shortly thereafter. Shares up 13% premarket.
Diffusion Pharmaceuticals (NASDAQ:DFFN)
will collaborate with the University of Virginia and the Integrated
Translational Research Institute of Virginia to evaluate Trans Sodium
Crocetinate in patients with COVID-19-associated acute respiratory
syndrome. Shares up 54% premarket.
Citius Pharmaceuticals (NASDAQ:CTXR) inks an exclusive six-month option agreement with a subsidiary of Novellus for a stem cell therapy for acute respiratory distress syndrome. Shares up 48% premarket.
https://seekingalpha.com/news/3557101-covidminus-19-related-actions-healthcare
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.